Novel approach for attenuation of pirfenidone-induced digestive symptoms : a respirable powder formulation of pirfenidone
Aim: Orally taken pirfenidone (PFD) often causes digestive symptoms. A respirable powder formulation of PFD (PFD-RP) was previously developed, and this study aimed to verify the risk of digestive symptoms after insufflation of PFD-RP. Materials & methods: Intestinal motility and gastrointestinal exposure levels was evaluated in PFD-RP (0.3-mg PFD/rat: a pharmacologically effective dose) and orally taken PFD (10-100 mg/kg) groups. Results & conclusion: Orally taken PFD at doses above 30 mg/kg significantly inhibited intestinal motility. In contrast, insufflated PFD-RP led to comparable intestinal motility in control group, and gastrointestinal exposure levels in PFD-RP group were markedly lower than those in orally taken PFD groups. Inhalation therapy using PFD-RP may be efficacious to reduce the risk of digestive symptoms frequently induced by orally taken PFD.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2021 |
|---|---|
| Erschienen: |
2021 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:12 |
|---|---|
| Enthalten in: |
Therapeutic delivery - 12(2021), 7 vom: 17. Juli, Seite 515-522 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Seto, Yoshiki [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
D7NLD2JX7U |
|---|
| Anmerkungen: |
Date Completed 05.07.2021 Date Revised 05.07.2021 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.4155/tde-2021-0027 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM326874283 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM326874283 | ||
| 003 | DE-627 | ||
| 005 | 20231225195533.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2021 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.4155/tde-2021-0027 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1089.xml |
| 035 | |a (DE-627)NLM326874283 | ||
| 035 | |a (NLM)34139888 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Seto, Yoshiki |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Novel approach for attenuation of pirfenidone-induced digestive symptoms |b a respirable powder formulation of pirfenidone |
| 264 | 1 | |c 2021 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 05.07.2021 | ||
| 500 | |a Date Revised 05.07.2021 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Aim: Orally taken pirfenidone (PFD) often causes digestive symptoms. A respirable powder formulation of PFD (PFD-RP) was previously developed, and this study aimed to verify the risk of digestive symptoms after insufflation of PFD-RP. Materials & methods: Intestinal motility and gastrointestinal exposure levels was evaluated in PFD-RP (0.3-mg PFD/rat: a pharmacologically effective dose) and orally taken PFD (10-100 mg/kg) groups. Results & conclusion: Orally taken PFD at doses above 30 mg/kg significantly inhibited intestinal motility. In contrast, insufflated PFD-RP led to comparable intestinal motility in control group, and gastrointestinal exposure levels in PFD-RP group were markedly lower than those in orally taken PFD groups. Inhalation therapy using PFD-RP may be efficacious to reduce the risk of digestive symptoms frequently induced by orally taken PFD | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 650 | 4 | |a digestive symptoms | |
| 650 | 4 | |a gastrointestinal motility | |
| 650 | 4 | |a inhalation | |
| 650 | 4 | |a pirfenidone | |
| 650 | 4 | |a pulmonary fibrosis | |
| 650 | 7 | |a Powders |2 NLM | |
| 650 | 7 | |a Pyridones |2 NLM | |
| 650 | 7 | |a pirfenidone |2 NLM | |
| 650 | 7 | |a D7NLD2JX7U |2 NLM | |
| 700 | 1 | |a Suzuki, Gen |e verfasserin |4 aut | |
| 700 | 1 | |a Aoki, Asako |e verfasserin |4 aut | |
| 700 | 1 | |a Kaneko, Yuuki |e verfasserin |4 aut | |
| 700 | 1 | |a Kato, Masashi |e verfasserin |4 aut | |
| 700 | 1 | |a Sato, Hideyuki |e verfasserin |4 aut | |
| 700 | 1 | |a Onoue, Satomi |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Therapeutic delivery |d 2010 |g 12(2021), 7 vom: 17. Juli, Seite 515-522 |w (DE-627)NLM203937082 |x 2041-6008 |7 nnns |
| 773 | 1 | 8 | |g volume:12 |g year:2021 |g number:7 |g day:17 |g month:07 |g pages:515-522 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.4155/tde-2021-0027 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 12 |j 2021 |e 7 |b 17 |c 07 |h 515-522 | ||